These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 5306426)
1. [Effect of sulfinpyrazone(Anturan) on the uric acid metabolism in malignant blood diseases]. de Carvalho RI; Givisiez AN; Cardoso JR Hospital (Rio J); 1969 Apr; 75(4):1343-55. PubMed ID: 5306426 [No Abstract] [Full Text] [Related]
2. [Use of the Port-a-cath subcutaneous central venous catheter in patients with malignant blood diseases]. la Cour Petersen E; Husegaard HC Ugeskr Laeger; 1986 Jun; 148(27):1672-5. PubMed ID: 3750449 [No Abstract] [Full Text] [Related]
3. [Complications during treatment of blood diseases with corticosteroid hormonal preparations]. Latysh VN; Khludeev NI Sov Med; 1974 Jun; 37(6):91-5. PubMed ID: 4527064 [No Abstract] [Full Text] [Related]
4. [Clinical findings and therapy of gout with special reference to the metabolic effects of sulfinpyrazone (Anturan) and allopurinol (Zyloric)]. Günther R; Knapp E Wien Klin Wochenschr; 1969 Nov; 81(45):817-20. PubMed ID: 5362152 [No Abstract] [Full Text] [Related]
5. [The treatment of chronic hemoblastosis with new cytostatic agents]. Quattrin N Minerva Med; 1966 Mar; 57(25):1141-3. PubMed ID: 5932017 [No Abstract] [Full Text] [Related]
7. [On the influence of Anturan on ric acid and plasma lipids in patients with gout]. Günther R; Herbst M; Knapp E; Siller K Wien Klin Wochenschr; 1968 Jun; 80(24):473-8. PubMed ID: 5692866 [No Abstract] [Full Text] [Related]
8. [Indomethacin and hematopoiesis. Antipyretic and antiphlogistic effects in hemoblastoses and various uncommon diseases]. Treske U Med Klin; 1968 Mar; 63(9):344-6. PubMed ID: 5247178 [No Abstract] [Full Text] [Related]
10. Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers. Pfister B; Imhof P; Wirz H Eur J Clin Pharmacol; 1978 Jun; 13(4):263-5. PubMed ID: 668783 [TBL] [Abstract][Full Text] [Related]
11. [Interaction of sulfinpyrazone (Anturan) and glibenclamide (Euglucon) in type II diabetic patients]. Kritz H; Najemnik C; Irsigler K Wien Med Wochenschr; 1983 May; 133(9):237-43. PubMed ID: 6408808 [TBL] [Abstract][Full Text] [Related]
12. Use of Rabenid for different indications. Nagy F Ther Hung; 1991; 39(2):90-2. PubMed ID: 1948784 [TBL] [Abstract][Full Text] [Related]
13. [Indomethacin in hemoblastosis]. Treske U Arzneimittelforschung; 1971 Nov; 21(11):1832-3. PubMed ID: 4944970 [No Abstract] [Full Text] [Related]
14. [Effect of long-term base therapy on the clinical picture of gout]. Baiatova KV Ter Arkh; 1981; 53(2):87-91. PubMed ID: 7221944 [No Abstract] [Full Text] [Related]
15. Comparison of the uricosuric effect of sulfinpyrazone (anturan) and zoxazolamine (flexin). MONTGOMERY DB; OGRYZLO MA Can Med Assoc J; 1960 Oct; 83(17):885-8. PubMed ID: 13772195 [No Abstract] [Full Text] [Related]
16. [On gout]. Schulze H Munch Med Wochenschr; 1966 Jan; 108(2):96-8. PubMed ID: 6013450 [No Abstract] [Full Text] [Related]
17. [Leukocyte transfusion in post-chemotherapy agranulocytosis observed in malignant blood diseases]. Goudemand M; Delmas-Marsalet Y; Bauters F Lille Med; 1968 Mar; 13(3):313-21. PubMed ID: 5759508 [No Abstract] [Full Text] [Related]
20. [Prevention of hyperuricemia and its complications with allopurinol, in the treatment of several hematologic diseases]. Rapado Errazti A; Torres González JA Rev Clin Esp; 1966 Nov; 103(4):296-301. PubMed ID: 5999583 [No Abstract] [Full Text] [Related] [Next] [New Search]